Research led by the Centenary Institute and the University of Technology Sydney (UTS) has identified a small RNA molecule called microRNA-21 as a therapeutic target, and its inhibition is a potential treatment for chronic obstructive pulmonary disease (COPD). Identified.
COPD, an inflammatory lung disease that makes breathing difficult, is often caused by smoking tobacco products and inhaling air pollution. This is the third leading cause of death in the world.
in frontClinical trials, Researchers have found elevated levels of microRNA-21 in experimental COPD models, including mice.The use of microRNA-21 inhibitors (antagomir-21) as a therapeutic treatment has been shown to reduce and ameliorate inflammation. Vital capacity Works with these models.
Researchers said that antagomir-21 reduced the expression of microRNA-21 and suppressed the influx of inflammatory cells (macrophages, neutrophils, lymphocytes) into the airways and lungs.Amplified lung cytokine production Inflammatory reaction, Was also suppressed by the use of antagomir-21.
Professor Phil Hansbro, lead author of the study and director of the 100th Anniversary UTS Inflammation Center, said their findings provided a whole new understanding of COPD.
“MicroRNA-21 is a common molecule that is expressed in most cells of the human body and regulates many important biological processes. However, our finding is that microRNA-21 levels increase with respect to COPD. It shows, “says Professor Hansbro.
“We believe that the development of new drugs that block microRNA-21 may offer a whole new therapeutic approach to the treatment of COPD.”
Professor Hansbro said the findings may address the limited effectiveness of current therapies in controlling or stopping the progression of COPD.
“The development of effective COPD therapies has been hampered by a lack of understanding of the underlying mechanisms of the disease. Our data define microRNA-21 as new. Therapeutic target And its inhibitor as a potential new treatment for this major, now refractory lung disease. “
The study is published in the journal Scientific translation medicine “To promote SATB1 / S100A9 / NF-kB axis via microRNA-21 Chronic obstructive pulmonary disease Cause. ”
The SATB1 / S100A9 / NF-kB axis via microRNA-21 promotes the etiology of chronic obstructive pulmonary disease. Scientific translation medicine (2021). DOI: 10.1126 /scitranslmed.aav7223
University of Technology Sydney
Quote: Researchers have obtained a new target for combating lung disease (November 2021) obtained from https://medicalxpress.com/news/2021-11-combat-lung-disease.html on November 24, 2021. 24th) was found
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Researchers Find New Targets to Fight Lung Disease
Source link Researchers Find New Targets to Fight Lung Disease